English
Segment disclosures
Company overviewTHERAVANCE BIOPHARMA, INC.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
5 dimension combinations 36 retained observations 11 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Collaborative Arrangement Revenue · Single Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=tbph:CollaborativeArrangementRevenueMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 20731000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 38430000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 74964000 | USD | 20260323 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 19990000 | USD | 20251112 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 54073000 | USD | 20251112 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 18695000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34083000 | USD | 20260811 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 64381000 | USD | 20260323 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 16868000 | USD | 20251112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 45627000 | USD | 20251112 | Open filing evidence |
Co Promote Agreement · Single Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=tbph:CoPromoteAgreementMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-04-01 – 2025-06-30 | 18695000 | USD | 20250813 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 34083000 | USD | 20250813 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 14256000 | USD | 20250813 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 28759000 | USD | 20250813 | Open filing evidence |
Licensing And Milestone · Single Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=tbph:LicensingAndMilestoneMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 32500000 | USD | 20260323 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7500000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 7500000 | USD | 20260811 | Open filing evidence |
License · Single Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:LicenseMember;us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-09-30 | 7500000 | USD | 20251112 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7500000 | USD | 20250813 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 7500000 | USD | 20250813 | Open filing evidence |
Single Reportable Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=tbph:SingleReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 20731000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 38430000 | USD | 20260811 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 17699000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 107464000 | USD | 20260323 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 19990000 | USD | 20251112 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 61573000 | USD | 20251112 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 26195000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 41583000 | USD | 20260811 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 15388000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 64381000 | USD | 20260323 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 16868000 | USD | 20251112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 45627000 | USD | 20251112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 14256000 | USD | 20250813 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 28759000 | USD | 20250813 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 14503000 | USD | 20250512 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 57424000 | USD | 20250307 | Open filing evidence |